Peripheral artery disease in patients with schizophrenia as compared to controls.

BACKGROUND: Patients with schizophrenia have an increased prevalence of risk factors for peripheral artery disease (PAD) and is expected to have an increased prevalence of PAD. PAD can be detected utilizing toe-brachial index (TBI) which screens for vascular pathology proximal to the toes. METHODS: Using a cross-sectional design, we defined the subpopulations: (1) Patients diagnosed with schizophrenia less than 2 years before inclusion (SCZ < 2), (2) Psychiatric healthy controls matched to subpopulation 1 on sex, age, and smoking status, and (3) Patients diagnosed with schizophrenia 10 or more years before inclusion (SCZ ≥ 10). TBI was calculated by dividing toe pressures by systolic brachial blood pressure, and PAD was defined by TBI < 0.70. Logistic regression analysis with PAD as outcome and sex, age, smoking status, BMI, skin temperature, diagnosis of schizophrenia, and comorbidities as explanatory variables was conducted. RESULTS: PAD was present in 26.2% of patients diagnosed with SCZ < 2 (17 of 65) and in 18.5% of psychiatric healthy controls (12 of 65) with no statistically significant difference in prevalence rates (p = 0.29). PAD was present in 22.0% of patients diagnosed with SCZ ≥ 10 (31 of 141). In logistic regression, patients diagnosed with SCZ < 2 had an increased odds of PAD with psychiatric healthy controls as reference (Odds ratio = 2.80, 95% confidence interval 1.09-7.23, p = 0.03). The analysis was adjusted for age, sex, smoking status, BMI and comorbidities such as hypertension, diabetes and heart disease. CONCLUSIONS: This study did not find statistically significant increased prevalence rates of PAD in patients with schizophrenia even though patients with SCZ were compared to psychiatric healthy controls using TBI. Utilizing logistic regression PAD was associated with schizophrenia diagnosis within the last 2 years, age and skin temperature. As PAD is initially asymptomatic, screening could be relevant in patients with schizophrenia if other risk factors are prevalent. Further large-scale multicenter studies are warranted to investigate schizophrenia as a potential risk factor for PAD. TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT02885792.

Prevalence and mortality among patients with COPD hospitalised by ambulance in the 2007-2018 period.

INTRODUCTION: Severe exacerbations in chronic obstructive pulmonary disease (COPD) may require acute medical attention by calling the emergency medical services (EMS) for an ambulance. The 30-day mortality for EMS patients with respiratory diseases appears to have stagnated, which may be due to changes in age, comorbidity or disease severity. We examined trends of occurrence, severity and mortality for EMS patients with COPD. METHODS: A historical population-based cohort study was conducted encompassing patients with COPD who requested an ambulance in the North Denmark Region in the 2007-2018 period. We described acute severity by oxygen saturation and respiratory rate at the arrival of the ambulance along with comorbidity and duration of hospitalisation. RESULTS: A total of 5,969 EMS patients with COPD were identified and the figure nearly doubled from 2007 to 2018. Age and comorbidity were higher in the last part of the period. Furthermore, the initial respiratory rate was higher, oxygen saturation was lower and the duration of hospitalisation was lower in the last part of the period. The 30-day mortality rose from 12.6% to 15.4%, but the odds ratio was not statistically higher and decreased after adjustment. CONCLUSIONS: COPD constituted increasing proportions of those admitted to hospital after calling the EMS. The mortality among EMS patients with COPD may be due to patients being older, having more comorbidities or being more severely acutely ill. The mortality suggests that COPD patients requesting an ambulance should be considered severely ill. FUNDING: none. TRIAL REGISTRATION: not relevant.